{"id":"hypercvad","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity (from doxorubicin)"},{"rate":null,"effect":"Neurotoxicity (from vincristine)"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HyperCVAD is an intensive combination chemotherapy regimen consisting of cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternated with high-dose methotrexate and cytarabine. These agents work through multiple mechanisms including alkylation, microtubule disruption, and antimetabolite activity to induce apoptosis in malignant cells. The regimen is designed for hematologic malignancies where intensive multi-agent chemotherapy provides superior outcomes.","oneSentence":"HyperCVAD is a chemotherapy regimen that combines multiple cytotoxic agents to kill rapidly dividing cancer cells through DNA damage and cell cycle disruption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:07.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Lymphoma"},{"name":"Chronic myeloid leukemia (CML) in blast phase"}]},"trialDetails":[{"nctId":"NCT05581030","phase":"PHASE1","title":"CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT07223190","phase":"PHASE3","title":"A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia","status":"NOT_YET_RECRUITING","sponsor":"Amgen","startDate":"2026-06-11","conditions":"Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia","enrollment":560},{"nctId":"NCT04994717","phase":"PHASE3","title":"Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Amgen","startDate":"2021-11-02","conditions":"Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)","enrollment":304},{"nctId":"NCT01184885","phase":"EARLY_PHASE1","title":"A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia, Burkitt Lymphoma","enrollment":7},{"nctId":"NCT06598722","phase":"PHASE2","title":"BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-07","conditions":"Lymphoblastic Lymphoma, Adult, Lymphoblastic Leukemia, Acute T-cell","enrollment":206},{"nctId":"NCT06250959","phase":"PHASE2","title":"RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.","status":"RECRUITING","sponsor":"Chen Suning","startDate":"2024-02-05","conditions":"ALL, Adult, Philadelphia-Negative ALL","enrollment":124},{"nctId":"NCT01527149","phase":"PHASE2","title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-12-06","conditions":"Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT00477412","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-03","conditions":"Mantle Cell Lymphoma","enrollment":107},{"nctId":"NCT05137860","phase":"PHASE4","title":"Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD","status":"UNKNOWN","sponsor":"Hospital General de Mexico","startDate":"2021-12-12","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease","enrollment":56},{"nctId":"NCT00299182","phase":"PHASE1, PHASE2","title":"Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-03","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT00581854","phase":"PHASE2","title":"Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2000-06","conditions":"Mantle Cell Lymphoma","enrollment":22},{"nctId":"NCT01219816","phase":"PHASE2","title":"Multi-centric Study","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2010-11","conditions":"B ALL, CD22+ Expression, Refractory B-ALL","enrollment":57},{"nctId":"NCT02578511","phase":"PHASE1","title":"Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)","status":"WITHDRAWN","sponsor":"Ehab L Atallah","startDate":"2017-06-29","conditions":"Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission","enrollment":""},{"nctId":"NCT01358253","phase":"PHASE4","title":"Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2010-12","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT01854372","phase":"PHASE2","title":"Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2013-06","conditions":"Newly Diagnosed Diffuse Large B-Cell Lymphoma, Intermediate (Burkitt-Like) Lymphoma","enrollment":""},{"nctId":"NCT00822731","phase":"NA","title":"Samsung Medical Center-Lymphoma Cohort Study","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-09","conditions":"Lymphoma","enrollment":953},{"nctId":"NCT00801580","phase":"PHASE2","title":"My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2008-03","conditions":"Lymphoid Leukemia","enrollment":3}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE LYMPHOCYTIC LEUKAEMIA REFRACTORY"},{"count":1,"reaction":"ELECTROCARDIOGRAM QT PROLONGED"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"PLATELET COUNT ABNORMAL"},{"count":1,"reaction":"PLEURAL EFFUSION"},{"count":1,"reaction":"SINUS TACHYCARDIA"},{"count":1,"reaction":"SUPRAVENTRICULAR TACHYCARDIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HyperCVAD","genericName":"HyperCVAD","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HyperCVAD is a chemotherapy regimen that combines multiple cytotoxic agents to kill rapidly dividing cancer cells through DNA damage and cell cycle disruption. Used for Acute lymphoblastic leukemia (ALL), Lymphoma, Chronic myeloid leukemia (CML) in blast phase.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}